RayKnowChina Research Map
Shortlist

Not yet recruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by National Cancer Center / Cancer Hospital, CAMS; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)National Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04736589, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 85 years; sex: women only

    Registered eligibility fields

  2. Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease.

    Inclusion criterion 3

  3. Patients with HER2-positive metastatic breast cancer who have progressed disease after trastuzumab treatment include the following four types of patients (Note: The following patients are in a parallel relationship):

    Inclusion criterion 4

    Patients with HER2-positive breast cancer who have progressed during adjuvant trastuzumab treatment after surgery; or

    Inclusion criterion 5

    Patients with HER2-positive breast cancer who have relapsed or metastasized after receiving adjuvant trastuzumab therapy; or

    Inclusion criterion 6

    HER2-positive recurrent or metastatic BC patients who have progressed after receiving at least 4 weeks of trastuzumab as first-line treatment ; or

    Inclusion criterion 7

    HER2-positive metastatic BC patients who have never been treated have progressed after receiving at least 4 weeks of trastuzumab as first-line treatment.

    Inclusion criterion 8

  4. ECOG PS score ≤2, estimated survival time ≥6 months, and can be followed-up;

    Inclusion criterion 10

  5. Total bilirubin ≤ 1.5 times the upper limit of normal value. Patients with known Gibert's disease can be included in the group if combined bilirubin ≤ 1.5 times the upper limit of normal value;

    Inclusion criterion 14

    AST and ALT ≤2.5 times the upper limit of the normal value; if there is liver metastasis, ≤5 times the upper limit of the normal value (the normal value is the normal value specified by this clinical trial center);

    Inclusion criterion 15

    ANC≥1.5 x 10\^3 /μL;

    Inclusion criterion 17

    Hemoglobin ≥9 g/dL.

    Inclusion criterion 19

  6. Patients with measurable disease as per RECIST 1.1 criteria;

    Inclusion criterion 11

  7. Hepatitis B or hepatitis C carriers, or other known chronic liver diseases; HIV positive;

    Exclusion criterion 7

    Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma;

    Exclusion criterion 11

  8. Female patients of childbearing age have a negative pregnancy test and voluntarily take effective and reliable contraceptive measures;

    Inclusion criterion 22

    Women during pregnancy or lactation;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04736589, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female, Aged > 18;
  • HER2-positive breast cancer are defined as immunohistochemical (IHC) testing as +++, or IHC++ with FISH testing of positive;
  • Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease.
  • Patients with HER2-positive metastatic breast cancer who have progressed disease after trastuzumab treatment include the following four types of patients (Note: The following patients are in a parallel relationship):
  • Patients with HER2-positive breast cancer who have progressed during adjuvant trastuzumab treatment after surgery; or
  • Patients with HER2-positive breast cancer who have relapsed or metastasized after receiving adjuvant trastuzumab therapy; or
  • HER2-positive recurrent or metastatic BC patients who have progressed after receiving at least 4 weeks of trastuzumab as first-line treatment ; or
  • HER2-positive metastatic BC patients who have never been treated have progressed after receiving at least 4 weeks of trastuzumab as first-line treatment.
  • Genetic testing shows that the PI3K/Akt/mTOR pathway related genes are mutated;
  • ECOG PS score ≤2, estimated survival time ≥6 months, and can be followed-up;
  • Patients with measurable disease as per RECIST 1.1 criteria;
  • Cardiopulmonary function is basically normal, LVEF≥50% within 4 weeks before starting treatment;
  • An adequate liver function with the following definition:
  • Total bilirubin ≤ 1.5 times the upper limit of normal value. Patients with known Gibert's disease can be included in the group if combined bilirubin ≤ 1.5 times the upper limit of normal value;
  • AST and ALT ≤2.5 times the upper limit of the normal value; if there is liver metastasis, ≤5 times the upper limit of the normal value (the normal value is the normal value specified by this clinical trial center);
  • Have sufficient baseline hematology parameters, defined as follows:
  • ANC≥1.5 x 10\^3 /μL;
  • Platelet count ≥100 x 10\^3/μL, if it is 75-100 x 10\^3/μL, it may be included in the group, as long as the doctors believe it can be included;
  • Hemoglobin ≥9 g/dL.
  • Coagulation Indicators: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 times the upper limit of normal, unless drugs known to change INR and aPTT are used;
  • No history of serious heart, kidney and other important organs and endocrine disease;
  • Female patients of childbearing age have a negative pregnancy test and voluntarily take effective and reliable contraceptive measures;
  • The patients voluntarily signed an informed consent form.

Exclusion Criteria:

Anyone who has one of the following conditions cannot be selected for this trial:

  • Participated in other clinical trials within 4 weeks;
  • Have used mTOR inhibitors in the past;
  • Previous use of Pyrotinib in first-line treatment stage; previous use of lapatinib is allowed;
  • Accompanied by immunosuppressant or chronic corticosteroid medication, or more than 25% bone marrow radiotherapy within 4 weeks;
  • Symptomatic CNS metastases or evidence of leptomeningeal disease;
  • Gastrointestinal dysfunction or gastrointestinal diseases (including active ulcers);
  • Hepatitis B or hepatitis C carriers, or other known chronic liver diseases; HIV positive;
  • Known hypersensitivity to any study medication
  • Women during pregnancy or lactation;
  • Left ventricular ejection fraction <50%; clinical manifestations of patients with obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency, and severe valvular disease;
  • Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma;
  • The researchers decide that any other medical, social or psychological conditions which are inappropriate to participate in this trial.

Quoted from ClinicalTrials.gov, NCT04736589, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04736589, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04736589